Breathing Better: Scaling up EU Prevention Policies for Respiratory Health
September 24, 2025
Breathing Better: Scaling up EU Prevention Policies for Respiratory Health Report from the EU Parliament event, September 23, 2025
Breathing Better: Scaling up EU Prevention Policies for Respiratory Health Report from the EU Parliament event, September 23, 2025
This event was organized as an interim update to the World Symposium on Pulmonary Hypertension (WSPH), which has traditionally been held every five years.
I recently attended the PVRI Drug Discovery & Development Symposium 2025 in Amsterdam, held 16–17 June and regarded as the smaller of PVRI’s two Hlagship
On February 4th and 5th, I hade the privilege to represent PHAEUROPE in two significant events at the European Parliament – the Healthy Lungs for
PHA Europe is pleased to share the exciting news that the European Medicines Agency (EMA) has approved WINREVAIR™ (sotatercept) for the treatment of Pulmonary Arterial
PHA recently held its 15th international PH conference in Indianapolis, Indiana. This gathering brought together a diverse group of about 1100 healthcare professionals, researchers, patients,
The pharmaceutical company Gossamer Bio, celebrates a significant achievement with the publication of its TORREY Phase 2 study results in the esteemed Lancet Respiratory Medicine
Approximately 150 pulmonary hypertension (PH) specialists convened in Barcelona in April 2024 for Ferrer’s 6th edition of the IMPAHCT meeting. Notably, Hall Skaara represented PHA
The FDA recently approved Opsynvi, developed by Johnson & Johnson, for treating pulmonary arterial hypertension (PAH) in adults, marking a significant advancement in PAH management.
Merck, also known as MSD outside of the United States and Canada, has announced the FDA approval of Winrevair™ (sotatercept), a groundbreaking biologic for the
The Saudi Association for Pulmonary Hypertension (SAPH) hosted its 17th annual conference in Riyadh, Saudi Arabia, from February 15 to 17, 2024. The conference featured
Ferrer annually hosts a conference known as IMPACHT (International Meeting on Pulmonary Hypertension Clinical Treatment) that caters to pulmonologists and cardiologists.
Due to the COVID pandemic, the annual PH European conference (APHEC) had to be run virtually. This has worked very well as we utilised an
Our conference hall is now available. Here you will be able to see presentations by leading PH specialist from last year’s conference and the presentations
Estonia, Tallinn – 01.10.2021 09:30 – 01.10.2021 20:00 [hybrid event] Years of dedication and collaboration within the pulmonary hypertension (PH) community have vastly increased our
The conference hall will be available from February 28th. Here you will be able to see presentations by leading PH specialist talking about the future
In the course of 2014 PHA Europe representatives were present at the two largest events in the fields of cardiology and respiratory medicine.
Three new drugs for pulmonary hypertension have been approved by the US and/or EU regulatory authorities in the course of the last year:
World Symposium on Pulmonary Hypertension – February 27 to March 1, 2013, Nice, France. The 5th World PH Symposium was the most important scientific event